I think it is more likely to account for the run up in the shareprice of late than the pullback. If this gets approved Cogstate will be signing deals left right and center to use Cognigram as a triage tool. These discussions must be going on at the moment. If Abucanumab is approved early next year medical professionals will need a triage tool almost at once, so they can work out who should be receiving the drug. You would think far sighted administrators would at least be having these discussions with Cogstate already.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
0.060(3.41%) |
Mkt cap ! $308.9M | |||
| Open | High | Low | Value | Volume |
| $1.77 | $1.86 | $1.76 | $400.6K | 221.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2522 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 3170 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |